Shares Outstanding (Quarterly) Chart

Historical Shares Outstanding (Quarterly) Data

View and export this data back to 2001. Start Trial.
Date Value
June 30, 2026 66.31M
March 31, 2026 65.86M
December 31, 2025 65.20M
September 30, 2025 64.47M
June 30, 2025 64.06M
March 31, 2025 63.29M
December 31, 2024 63.16M
September 30, 2024 62.31M
June 30, 2024 62.28M
March 31, 2024 62.15M
December 31, 2023 61.85M
September 30, 2023 61.85M
June 30, 2023 59.58M
March 31, 2023 59.58M
December 31, 2022 59.43M
September 30, 2022 59.43M
June 30, 2022 59.40M
March 31, 2022 59.39M
December 31, 2021 59.34M
September 30, 2021 59.34M
June 30, 2021 59.28M
March 31, 2021 57.19M
December 31, 2020 57.08M
September 30, 2020 57.08M
June 30, 2020 56.89M
Date Value
March 31, 2020 57.03M
December 31, 2019 56.89M
September 30, 2019 56.66M
June 30, 2019 56.59M
March 31, 2019 45.59M
December 31, 2018 41.19M
September 30, 2018 41.14M
June 30, 2018 40.63M
March 31, 2018 37.65M
December 31, 2017 35.79M
September 30, 2017 35.64M
June 30, 2017 34.97M
March 31, 2017 34.67M
December 31, 2016 32.91M
September 30, 2016 29.40M
June 30, 2016 29.28M
March 31, 2016 28.98M
December 31, 2015 28.82M
September 30, 2015 23.93M
June 30, 2015 23.79M
March 31, 2015 23.73M
December 31, 2014 22.28M
September 30, 2014 22.12M
June 30, 2014 22.03M
March 31, 2014 21.91M

Shares Outstanding Definition

The volume of stock shares issued by the company and in the hands of the public. This number entails how much is being traded in the open market. A decreasing shares outstanding over time may be the result of company buybacks. Companies frequently make stock buybacks and retire those buybacks as treasury stock.

Read full definition.

Shares Outstanding (Quarterly) Range, Past 5 Years

View Shares Outstanding (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shares Outstanding (Quarterly) Benchmarks

View Shares Outstanding (Quarterly) Benchmarks
Start Trial
Mirum Pharmaceuticals, Inc. 64.75M
ACADIA Pharmaceuticals, Inc. 172.13M
Alnylam Pharmaceuticals, Inc. 133.73M
Anika Therapeutics, Inc. 13.38M
Savara, Inc. 205.40M